Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | APEX1 | P27695 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ENO1 | P06733 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31456330 | 0.80 | CYP3A4 (0.50) | TDP1APEX1TSHRCYP3A4MAPT | |
| SCHEMBL2018376 | 0.77 | SMN1; SMN2 (0.34) | TDP1APEX1TSHRCYP3A4MAPT | |
| SCHEMBL20525267 | 0.74 | ACE (0.35) | TDP1APEX1TSHRCYP3A4MAPT | |
| SCHEMBL19559460 | 0.74 | MAPT (0.44) | TDP1APEX1TSHRCYP3A4MAPT | |
| SCHEMBL4480285 | 0.72 | TSHR (0.34) | TDP1APEX1TSHRCYP3A4MAPT | |
| SCHEMBL2687742 | 0.72 | TSHR (0.46) | APEX1TSHR | |
| SCHEMBL19868415 | 0.72 | CYP3A4 (0.31) | TDP1APEX1TSHRCYP3A4MAPT | |
| SCHEMBL2686288 | 0.71 | PARP1 (0.34) | TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL253915 | 0.70 | — | — | |
| SCHEMBL1897868 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10093623-B2 | Cyclic amides as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2018-10-09 | — | — | US | claimed |
| EP-1444202-B1 | NOVEL METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| US-7132434-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2006-11-07 | — | — | US | disclosed |
| US-20050026990-A1 | Novel metalloproteinase ihibitors | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | US | disclosed |
| EP-1444202-A1 | NOVEL METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040098-A1 | NOVEL METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026990-A1 | Novel metalloproteinase ihibitors | MMP12, MMP1, MMP16 | TDP1 3169/4885APEX1 3783/4885TSHR 4227/4885 |
| US-10093623-B2 | Cyclic amides as MetAP-2 inhibitors | METAP2, METAP1, LNPEP | TDP1 2635/4885APEX1 1514/4885TSHR 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.